Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 11, 2009

Duke University and Jubilant Plan on Initiating a Drug and Biomarker Collaboration

  • Duke University and India-based Jubilant Organosys signed a letter of intent to develop a partnership that will expedite translation of discoveries by Duke scientists into clinical therapies. Definitive agreements are expected to be completed by the first quarter of 2010.

    The parties plan on working together for five years with the objective of developing four or five therapeutic programs toward the clinical stage. They will also ally on biomarker research and validation studies.

    Duke and Jubilant will jointly select and manage certain translational research projects that can leverage the the university’s expertise. Development capabilities including funding will come from Jubilant. Both parties intend to monetize successful drug candidates by licensing or partnering as appropriate to receive milestones and/or royalties.

    Jubilant and Duke will also collaborate on two biomarker studies to be conducted in Kolkata, India. One project will focus on the development of a cohort to gain insights into the clinical and molecular characteristics of several chronic diseases highly prevalent in the Indian population. The investigators will work to better understand these diseases in the context of people moving from rural to urban settings.

    The second study will validate, in an Indian population with heart disease and diabetes, metabolomic biomarker signatures found to be associated with insulin resistance and cardiovascular disease in Caucasian populations. Jubilant will fund the pilot phase of these studies in India.

     



Related content

Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »